A framework for identification of on- and off-target transcriptional responses to drug treatment
暂无分享,去创建一个
Erik Arner | Takahiro Arakawa | Satoshi Takizawa | Michiel de Hoon | Harukazu Suzuki | M. Furuno | T. Arakawa | E. Arner | M. D. de Hoon | S. Takizawa | Yi Huang | Harukazu Suzuki | Masaaki Furuno | Yi Huang | Michiel J. L. de Hoon
[1] William DuMouchel,et al. Bayesian Data Mining in Large Frequency Tables, with an Application to the FDA Spontaneous Reporting System , 1999 .
[2] C. Stancu,et al. Statins: mechanism of action and effects , 2001, Journal of cellular and molecular medicine.
[3] B. Rovin,et al. A novel interleukin-8 polymorphism is associated with severe systemic lupus erythematosus nephritis. , 2002, Kidney international.
[4] G. Thorgeirsson,et al. Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S) , 2004, The Lancet.
[5] U. Pati,et al. Over‐expression of TATA binding protein (TBP) and p53 and autoantibodies to these antigens are features of systemic sclerosis, systemic lupus erythematosus and overlap syndromes , 2004, Clinical and experimental immunology.
[6] Pablo Tamayo,et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[7] G. Baumann,et al. Effect of statins on the proteasomal activity in mammalian endothelial and vascular smooth muscle cells. , 2005, Biochemical pharmacology.
[8] Paul A Clemons,et al. The Connectivity Map: Using Gene-Expression Signatures to Connect Small Molecules, Genes, and Disease , 2006, Science.
[9] J. Owczarek,et al. Statins: a new insight into their mechanisms of action and consequent pleiotropic effects. , 2007, Pharmacological reports : PR.
[10] P. Macfarlane,et al. Long-term follow-up of the West of Scotland Coronary Prevention Study. , 2007, The New England journal of medicine.
[11] C. Robert,et al. Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor. , 2008, Archives of dermatology.
[12] Jesse A Berlin,et al. Adverse event detection in drug development: recommendations and obligations beyond phase 3. , 2008, American journal of public health.
[13] C. Heng,et al. Effects of atherogenic diet and atorvastatin treatment on gene expression profiles in the C57BL/6J mouse liver. , 2008, Gene expression.
[14] Yan Leng,et al. Multiple roles of HDAC inhibition in neurodegenerative conditions , 2009, Trends in Neurosciences.
[15] L. Groop,et al. Epigenetics: A Molecular Link Between Environmental Factors and Type 2 Diabetes , 2009, Diabetes.
[16] Martin S. Taylor,et al. The transcriptional network that controls growth arrest and differentiation in a human myeloid leukemia cell line , 2009, Nature Genetics.
[17] Sabrina Koperski,et al. This material is the copyright of the original publisher. Unauthorised copying and distribution is prohibited. Amyotrophic Lateral Sclerosis-Like Conditions in Possible Association with Cholesterol-Lowering Drugs , 2009 .
[18] Hong Wang,et al. The FOX transcription factors regulate vascular pathology, diabetes and Tregs. , 2009, Frontiers in bioscience.
[19] Yasuo Ohashi,et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials , 2010, The Lancet.
[20] Aaron R. Quinlan,et al. Bioinformatics Applications Note Genome Analysis Bedtools: a Flexible Suite of Utilities for Comparing Genomic Features , 2022 .
[21] Mark D. Robinson,et al. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data , 2009, Bioinform..
[22] Han-Chang Huang,et al. Targeting HDACs: A Promising Therapy for Alzheimer's Disease , 2011, Oxidative medicine and cellular longevity.
[23] Xiaohong Chen,et al. Statins: Multiple neuroprotective mechanisms in neurodegenerative diseases , 2011, Experimental Neurology.
[24] M. Vizcaychipi,et al. Statins: the role in the treatment and prevention of Alzheimer's neurodegeneration. , 2011, Journal of Alzheimer's disease : JAD.
[25] Jianghua Chen,et al. Dual effects of statins therapy in systemic lupus erythematosus and SLE-related atherosclerosis: the potential role for regulatory T cells. , 2012, Atherosclerosis.
[26] P Ryan,et al. Novel Data‐Mining Methodologies for Adverse Drug Event Discovery and Analysis , 2012, Clinical pharmacology and therapeutics.
[27] Gang Xiao,et al. Signification of Hypermethylated in Cancer 1 (HIC1) as Tumor Suppressor Gene in Tumor Progression , 2012, Cancer Microenvironment.
[28] John J. McNeil,et al. The Value of Patient-Centred Registries in Phase IV Drug Surveillance , 2010, Pharmaceutical Medicine.
[29] Carsten O. Daub,et al. MOIRAI: a compact workflow system for CAGE analysis , 2014, BMC Bioinformatics.
[30] D. Ye,et al. E2F1: a potential therapeutic target for systematic lupus erythematosus , 2014, Rheumatology International.
[31] T. Steele,et al. Statins inhibit proliferation and cytotoxicity of a human leukemic natural killer cell line , 2013, Biomarker Research.
[32] Charity W. Law,et al. voom: precision weights unlock linear model analysis tools for RNA-seq read counts , 2014, Genome Biology.
[33] R. Heltsley,et al. Urine drug testing of chronic pain patients. V. Prevalence of propoxyphene following its withdrawal from the United States market. , 2013, Journal of analytical toxicology.
[34] H. Grover,et al. Are statins really wonder drugs? , 2014, Journal of the Formosan Medical Association = Taiwan yi zhi.
[35] Cesare Furlanello,et al. A promoter-level mammalian expression atlas , 2015 .
[36] Prasad Kulkarni,et al. How Drugs are Developed and Approved by the FDA: Current Process and Future Directions , 2014, The American Journal of Gastroenterology.
[37] V. Trajković,et al. Statin-mediated inhibition of cholesterol synthesis induces cytoprotective autophagy in human leukemic cells. , 2015, European journal of pharmacology.
[38] Pau-Chung Chen,et al. Statin reduces mortality and morbidity in systemic lupus erythematosus patients with hyperlipidemia: A nationwide population-based cohort study. , 2015, Atherosclerosis.
[39] T. Hamazaki,et al. Statins stimulate atherosclerosis and heart failure: pharmacological mechanisms , 2015, Expert review of clinical pharmacology.
[40] D. Slakey,et al. The impact of statins on biological characteristics of stem cells provides a novel explanation for their pleiotropic beneficial and adverse clinical effects. , 2015, American journal of physiology. Cell physiology.
[41] M. Obeidat,et al. Impact of Statins on Gene Expression in Human Lung Tissues , 2015, PloS one.
[42] Alessandro Didonna,et al. The promise and perils of HDAC inhibitors in neurodegeneration , 2014, Annals of clinical and translational neurology.
[43] Michael J. Keiser,et al. Systems pharmacology augments drug safety surveillance , 2014, Clinical pharmacology and therapeutics.
[44] Samik Ghosh,et al. Elucidation of the molecular mechanisms underlying adverse reactions associated with a kinase inhibitor using systems toxicology , 2015, npj Systems Biology and Applications.
[45] Jinkai Xu,et al. Simvastatin induces growth inhibition and apoptosis in HepG2 and Huh7 hepatocellular carcinoma cells via upregulation of Notch1 expression. , 2015, Molecular medicine reports.
[46] R. W. Hansen,et al. Journal of Health Economics , 2016 .
[47] Christos G Mihos,et al. Effects of Statin Therapy in Patients with Systemic Lupus Erythematosus , 2016, Southern medical journal.
[48] S. Grundy. Primary prevention of cardiovascular disease with statins: Assessing the evidence base behind clinical guidance , 2016 .
[49] S. Kimbung,et al. High expression of cholesterol biosynthesis genes is associated with resistance to statin treatment and inferior survival in breast cancer , 2016, Oncotarget.
[50] Junqiang Yan,et al. Neuroprotective mechanisms of statins in neurodegenerative diseases , 2016 .
[51] S. Ostad,et al. Investigation of simvastatin-induced apoptosis and cell cycle arrest in cancer stem cells of MCF-7. , 2016, Journal of cancer research and therapeutics.
[52] Amber Jessup,et al. Key cost drivers of pharmaceutical clinical trials in the United States , 2016, Clinical trials.
[53] Chiehfeng Chen,et al. Lovastatin lowers the risk of breast cancer: a population-based study using logistic regression with a random effects model , 2016, SpringerPlus.
[54] Y. Terauchi,et al. Lipid-lowering agents inhibit hepatic steatosis in a non-alcoholic steatohepatitis-derived hepatocellular carcinoma mouse model. , 2016, European journal of pharmacology.
[55] Douglas K Owens,et al. Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: US Preventive Services Task Force Recommendation Statement. , 2016, JAMA.
[56] Jie Luo,et al. Discovery of a potent HMG-CoA reductase degrader that eliminates statin-induced reductase accumulation and lowers cholesterol , 2018, Nature Communications.